

CURRICULUM VITAE FOR ACADEMIC PROMOTION

The Johns Hopkins University School of Medicine



June 17, 2022

Amy E. DeZern, MD, MHS

DEMOGRAPHIC AND PERSONAL INFORMATION

Current Appointments

University

2018-present Associate Professor of Oncology and Medicine, Department of Oncology
Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine

Hospital

2009-present Active Staff and Attending Physician, The Johns Hopkins Hospital, Baltimore, MD

Personal Data

The Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Bunting-Blaustein Cancer Research Building
1650 Orleans Street, Room 3M87
Baltimore, MD 21287
Tel (443) 287-2935
Tel (410) 502-7208
Fax (410) 614-7279
Email: adezern1@jhmi.edu

Education and Training

2000 B.S. Magna Cum Laude in Chemistry, University of Texas, Austin TX
2005 M.D., Johns Hopkins University School of Medicine, Baltimore MD
2006 Intern, Osler Medical Service, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore MD
2008 Resident Osler Medical Service, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore MD
2009 Fellow, Medical Oncology and Hematology, Johns Hopkins University School of Medicine
2011 Masters of Health Science, Clinical Investigation, Johns Hopkins Bloomberg School of Public Health, Baltimore MD
2012 Fellow, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center

Professional Experience

2009-2010 Instructor of Medicine and Assistant Chief of Service, Johns Hopkins University, Baltimore MD
2012-2018 Assistant Professor Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore MD
2018-present Associate Professor Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore MD

PUBLICATIONS

Original Research

1. Espinoza SE, Guo H, Fedarko N, **DeZern A**, Fried LP, Xue QL, Leng S, Beamer B, Walston JD. Glutathione peroxidase enzyme activity in aging. *J Gerontol A Biol Sci Med Sci*. 2008;63(5):505-9. PMID: 18511755. *Contributed to laboratory experiments and data management.*
2. **DeZern AE**, Luznik L, Fuchs EJ, Jones RJ, Brodsky RA. Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. *Bone Marrow Transplant*. 2011;46(7):1012-3. PMID: 20838390. *This report is the*

initial therapeutic experience with post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia which has become a major focus of my career.

3. **DeZern AE**, Sung A, Kim S, Smith BD, Karp JE, Gore SD, Jones RJ, Fuchs E, Luznik L, McDevitt M, Levis M. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. *Biol Blood Marrow Transplant.* 2011;17(9):1404-9. PMID: 21324374. *This article is one of earliest descriptions of the use of transplantation at CR1 to improve the outcomes in poor risk AML with FLT3. This paper forms the conceptual platform for my investigations in use of transplant to markedly alter outcomes in poor risk diseases.*
4. **DeZern AE**, Petri M, Drachman DB, Kerr D, Hammond ER, Kowalski J, Tsai HL, Loeb DM, Anhalt G, Wigley F, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. *Medicine (Baltimore).* 2011;90(2):89-98. PMID: 21358440. *This article reports the use of cyclophosphamide as a novel treatment for aplastic anemia, a bone marrow failure syndrome that represents an important focus for my career. This was the largest such series.*
5. **DeZern AE**, Dorr D, Brodsky RA. Predictors of Hemoglobin Response to Eculizumab Therapy in Paroxysmal Nocturnal Hemoglobinuria. *Eur J Haematol.* 2013;90(1):16-24. PMID: 23046169.
6. **DeZern AE**, Styler MJ, Drachman DB, Hummers LK, Jones RJ, Brodsky RA. Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases. *Am J Blood Res.* 2013;3(1):84-90. PMID: 23358715.
7. **DeZern AE**, Pu J, McDevitt MA, Jones RJ, Brodsky RA. Burst-Forming Unit-Erythroid Assays (BFU-E) To Distinguish Cellular Bone Marrow Failure Disorders. *Exp Hematol.* 2013;41(9):808-16. PMID: 23660070. *This manuscript describes the use of BFU-E colony forming assays in cellular marrow failure and is now a routinely utilized CLLA-certified test based on my work. The distinctions between forms of bone marrow failures has become a major area importance to my career.*
8. **DeZern AE**, Symons HJ, Resar LS, Borowitz MJ, Armanios MY, Brodsky RA. Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromes. *Eur J Haematol* 2014;92(6):467-70. PMID: 24612308. *This manuscript describes the use a clonal population of glycosylphosphatidylinositol anchor protein deficient cells in hypocellular marrow failure to distinguish forms of aplastic anemia, which has had an impact on the utilization of this testing to guide investigations of the etiology of aplastic anemia and therapy.*
9. **DeZern AE**, Uknis M, Yuan X, Mukhina GL, Varela J, Saye J, Pu J, Brodsky RA. Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria. *Exp Hematol.* 2014;42(10):857-861. PMID:25034232
10. Frank SM, Wick EC, **DeZern AE**, Ness PM, Wasey JO, Pippa AC, Dackiw E, Resar LM. Risk-adjusted clinical outcomes in patients enrolled in a bloodless program. *Transfusion.* 2014;54(10 Pt 2):2668-77. PMID: 24942198. *Contributed to data analysis and manuscript writing and revision.*
11. Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, **DeZern AE**, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. *Blood.* 2014;124(25):3817-27. PMID: 25316679. *Participated in study enrollment and manuscript revision.*
12. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, **DeZern A**, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. *Cancer.* 2015;121(6):876-82. PMID: 25410759. *Participated in study enrollment and manuscript revision.*
13. McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL, Kanakry CG, Perica K, Symons HJ, Brodsky RA, Gladstone DE, Huff CA, Pratz KW, Prince GT, **DeZern AE**, Gojo I, Matsui WH, Borrello I, McDevitt MA, Swinnen LJ, Smith BD, Levis MJ, Ambinder RF, Luznik L, Jones RJ, Fuchs EJ, Kasamon YL. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. *Blood.* 2015;125(19):3024-31. PMID: 25814532. *Participated in study enrollment and manuscript revision.*
14. Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, **DeZern A**, Maciejewski JP, List AF, Komrokji RS, MDS Clinical Research Consortium (Funded by Edward P. Evans Foundation). Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better? *Am J Hematol.* 2015;90(11):1036-40. PMID: 26284571. *Participated in study enrollment and manuscript revision.*
15. Kasamon YL, Bolaños-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, Rosner GL, Brodsky RA, Perica K, Smith BD, Gladstone DE, Swinnen LJ, Showel MM, Matsui WH, Huff CA, Borrello I, Pratz KW, McDevitt MA, Gojo I, **DeZern AE**, Shanbhag S, Levis MJ, Luznik L, Ambinder RF, Fuchs EJ, Jones RJ. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. *J Clin Oncol.* 2015;33(28):3152-61. PMID: 26261255. *Participated in study*

enrollment and manuscript revision.

16. Gorgy AL, Jonassaint NL, Stanley SE, Koteish A, **DeZern AE**, Walter JE, Sopha SC, Hamilton JP, Hoover-Fong J, Chen AR, Anders RA, Kamel IR, Armanios M. Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders. *Chest*. 2015;148(4):1019-26. PMID: 26158642. *Participated in study enrollment, analysis and manuscript preparation.*
17. Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, **DeZern AE**, Zell K, Zimmerman C, Al Ali N, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA. The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes at the Time of Hypomethylating Agent Failure. *Haematologica*. 2016;101(6):e224-7. PMID: 26992944. *Participated in study enrollment and manuscript revision.*
18. Gondek LP, Zheng G, Ghiaur G, **DeZern AE**, Matsui W, Yegnasubramian S, Lin MT, Levis M, Eshleman JR, Varadhan R, Tucker N, Jones R, Gocke CD. Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. *Leukemia*. 2016;30(9):1916-20. PMID: 26975880. *Contributed to data analysis and manuscript writing and revision.*
19. Klein OR, Chen AR, Gamper C, Loeb D, Zambidis E, Llosa N, Huo J, **DeZern AE**, Steppan D, Robey N, Holuba MJ, Cooke KR, Symons HJ. Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders. *Biol Blood Marrow Transplant*. 2016;22(5):895-901. PMID: 26860634. *Participated in analysis and manuscript preparation.*
20. Padron E, **DeZern A**, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, Sekeres MA, Komrokji RS, Myelodysplastic Syndrome Clinical Research Consortium. A Multi-Institution Phase 1 Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). *Clin Cancer Res*. 2016;22(15):3746-54. PMID: 26858309. *Participated in study design, study enrollment, manuscript writing and revision.*
21. Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, **DeZern AE**, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS; MDS Clinical Research Consortium. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. *Leuk Res*. 2016;41:43-7. PMID: 26777537. *Participated in study design, study enrollment, manuscript writing and revision.*
22. Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Ali N, Zimmerman C, Roboz G, **DeZern A**, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, List A, Komrokji R; MDS Clinical Research Consortium. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. *Leukemia*. 2016;30(3):649-57. PMID: 26464171. *Participated in study design, study enrollment, manuscript writing and revision.*
23. **DeZern AE**, Williams K, Zahurak M, Hand W, Stephens RS, King KE, Frank SM, Ness PM. Red blood cell transfusion triggers in acute leukemia: A randomized pilot study. *Transfusion*. 2016;56(7):1750-7. Epub 2016. PMID: 27198129. *This is the first randomized study in a hematologic malignancies population looking at feasibility of reduction in transfusion burden and represents the preliminary work for future proposals as a portion of my research focuses on the supportive therapies for myeloid diseases.*
24. Gamper CJ, Takemoto CM, Chen AR, Symons HJ, Loeb DM, Casella JF, **DeZern AE**, King KE, McGonigle AM, Jones RJ, Brodsky RA. High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia. *J Pediatr Hematol Oncol*. 2016;38(8):627-635. PMID: 27467367. *Participated in study design, manuscript writing and revision.*
25. Stanley SE, Gable DL, Wagner CL, Carlile TM, Hanumanthu VS, Podlevsky JD, Khalil SE, **DeZern AE**, Rojas-Duran MF, Applegate CD, Alder JK, Parry EM, Gilbert WV, Armanios M. Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema. *Sci Transl Med*. 2016;8(351):351ra107. PMID: 27510903. *Participated in manuscript revision.*
26. **DeZern AE**, Zeidan AM, Barnard J, Hand W, Al Ali N, Brown F, Zimmerman C, Roboz GJ, Garcia-Manero G, Steensma DP, Komrokji RS, Sekeres MA. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC). *Leuk Lymphoma*. 2017;58(6):1325-1331. Epub 2016 Oct 24. PMID: 27774847.
27. Gladstone DE, Petri M, Bolaños-Meade J, **DeZern AE**, Jones RJ, Fine D, Brodsky RA. Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation. *Lupus*. 2017;26(7):773-776. Epub 2016 Sep 30. PMID: 27687020. *Participated in study enrollment and manuscript writing.*
28. McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai HL, Showel MM, Kanakry JA, Symons HJ, Gojo I, Smith BD, Bettinotti MP, Matsui WH, **DeZern AE**, Huff CA, Borello I, Pratz KW, Gladstone DE, Swinnen LJ, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Comparable composite end-points after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

- Haematologica*. 2017;102(2):391-400. Epub 2016 Oct 20. PMID: 27846611. *Participated in study enrollment and manuscript revision.*
29. Pine AB, Lee EJ, Sekeres M, Steensma DP, Zelterman D, Prebet T, **DeZern A**, Komrokji R, Litzow M, Luger S, Stone R, Erba HP, Garcia-Manero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, Hendrickson JE, Gore SD, Zeidan AM. Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. *Transfusion*. 2017;57(2): 289-295. Epub 2016 Nov 22. PMID: 27878822. *Participated in study data contribution and manuscript writing.*
 30. **DeZern AE**, Zahurak M, Symons H, Cooke K, Jones RJ, Brodsky RA. Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia. *Bio Blood Marrow Transplant*. 2017;23(3):498-504. Epub 2016 Dec 21. PMID: 28013015. *This is the first and largest US series using a uniform conditioning regimen, mismatched donors and post-transplant cyclophosphamide as novel treatment for relapsed and refractory aplastic anemia. This represents an important focus for my career as well as platform for the national clinical trial of the same for which I am the study chair through the BMTCTN.*
 31. Zeidan AM, Smith BD, Carraway HE, Gojo I, **DeZern A**, Gore SD. A phase 2 trial of high dose of lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. *Br J Haematol*. 2017;176(2):241-247. Epub 2016 Oct 28. PMID: 27790720. *Participated in trial design, study enrollment, data analysis, manuscript writing and revision.*
 32. Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, **DeZern AE**, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes. *Cancer*. 2017;123(6):994-1002. Epub 2017 Jan 17. PMID: 28094841. *Participated in study enrollment and manuscript writing.*
 33. Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, **DeZern A**, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs. de novo myelodysplastic syndromes: A report on behalf of the MDS clinical research consortium. *Leukemia*. 2017;31(6):1391-1397. Epub 2017 Jan 23. PMID: 28111463. *Participated in study enrollment and manuscript writing.*
 34. Gojo, I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford A, Smith BD, Gore SD, Caraway HE, Showel MM, Levis MJ, **DeZern AE**, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufman SH, Chen A, Karp JE. A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. *Clin Can Research*. 2017;23(3):697-706. Epub 2016 Aug 8. PMID: 27503200. *Participated in study enrollment, manuscript writing and revision.*
 35. Smith BD, **DeZern AE**, Bastian A, Durie B. Meaningful Endpoints for Therapies Approved for Hematologic Malignancies. *Cancer*. 2017;123(10):1689-1694. Epub 2017 Feb 21. PMID: 28222220. *Participated in conception, data analysis, and manuscript writing.*
 36. **DeZern AE**, Binder G, Rizvi S, Corvino FA, Arikaian SR, Surinach A, Lee J, Smith BD. Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes. *Leuk Lymphoma*. 2017; 58(11):2649-2656. PMID: 28482722.
 37. Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, **DeZern A**, Roboz G, Kantarjian H, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. *Blood*. 2017;130(13):1514-1522. Epub 2017 Aug 3. PMID: 28774880. *Participated in study enrollment and manuscript writing.*
 38. Christenson ES, Dalton BW, Chu D, Waters I, Cravero K, Zabransky DJ, **DeZern AE**, Park BH. Single-Nucleotide Polymorphism leading to false allelic fraction by droplet digital PCR. *Clin Chem*. 2017;63(8):1370-1376. Epub 2017 Jun 14. PMID: 28615231. *Participated in conception, sample acquisition and manuscript writing.*
 39. **DeZern AE**, Binder G, Ni Q, McGuire M, Smith BD. Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes. *Leuk Res*. 2017;63:10-14. Epub 2017 Oct 18. PMID: 29078080.
 40. Norsworthy KJ, **DeZern AE**, Tsai HL, Hand WA, Varadhan R, Gore SD, Gojo I, Pratz K, Carraway HE, Showel M, McDevitt MA, Gladstone D, Ghiur G, Prince G, Seung AH, Benani D, Levis MJ, Karp JE, Smith BD. Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature. *Leuk Res*. 2017;61:25-32. Epub 2017 Aug 30. PMID: 28869816. *Participated in conception, data analysis, and manuscript writing.*
 41. **DeZern AE**, Borowitz MJ. ICCS/ESCCA Consensus Guidelines to detect GPI-Deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders - Part 1-clinical utility. *Cytometry B Clin Cytom*. 2018;

- 94(1):16-22. PMID: 29236352.
42. Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, **DeZern AE**, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. *Lancet Haematol.* 2018;5(2):e63-e72. Epub 2018 Jan 10. PMID: 29331635. *Participated in patient accrual, data analysis, and manuscript writing.*
 43. Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, Bolaños-Meade J, Fuchs EJ, Wagner-Johnston N, Swinnen LJ, Huff CA, Matsui WH, Gladstone DE, McCurdy SR, Borrello I, Gocke CB, Shanbhag S, Cooke KR, Ali SA, Brodsky RA, **DeZern AE**, Luznik L, Jones RJ, Ambinder RF. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. *Biol Blood Marrow Transplant.* 2018;24(5):1099-1102. Epub 2018 Feb 13. PMID: 29452245. *Participated in patient accrual, data analysis, and manuscript writing.*
 44. Alder JK, Hanumanthu VS, Strong MA, **DeZern AE**, Stanley SE, Takemoto CM, Danilova L, Applegate CD, Bolton SG, Mohr DW, Brodsky RA, Casella JF, Greider CW, Jackson JB, Armanios M. Diagnostic utility of telomere length testing in a hospital-based setting. *Proc Natl Acad Sci USA.* 2018;115(10):E2358-E2365. Epub 2018 Feb 20. PMID: 29463756. *Participated in patient accrual, data analysis, and manuscript writing.*
 45. Zeidan AM, Knaus HA, Robinson TM, Towler AM, Warren EH, Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, **DeZern AE**, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD. A multi-center Phase 1 trial of ipilimumab in patients with myelodysplastic syndrome following hypomethylating agent failure. *Clin Cancer Res.* 2018;24(15):3519-3527. Epub 2018 May 1. PMID: 29716921. *Participated in patient accrual, data analysis, and manuscript writing.*
 46. **DeZern AE**, Jones RJ, Brodsky RA. Eculizumab Bridging Before Bone Marrow Transplant for Marrow Failure Disorders is Safe and Does Not Limit Engraftment. *Biol Blood Marrow Transplant.* 2018;24(12):e26-e30. Epub 2018 Jul 26. PMID: 30055352.
 47. Benton CB, Khan M, Sallman D, Nazha A, Noguera González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E1, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, **DeZern A**, Roboz G, Sekeres M, Andreeff M1, Kantarjian H, Komrokji RS, Garcia-Manero G. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. *Am J Hematol.* 2018;93(10):1245-1253. Epub 2018 Sep 26. PMID: 30051599. *Participated in patient accrual, data analysis, and manuscript writing.*
 48. Migdady Y, Barnard J, Al Ali N, Steensma DP, **DeZern A**, Roboz G, Garcia-Manero G, Sekeres MA, Komrokji RS. Clinical Outcomes with Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis. *Clin Lymphoma Myeloma Leuk.* 2018;18(8):528-532. Epub 2018 May 26. PMID: 29937400. *Participated in patient accrual, data analysis, and manuscript writing.*
 49. Ball B, Komrokji RS, Ades L, Sekeres MA, **DeZern AE**, Pleyer L, Vey N, Almeida A, Germing U, Cluzeau T, Platzbecker U, Gore SD, Fenaux P, Prebet T. Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. *Blood.* 2018;2(16):2063-2071. PMID: 30120104. *Participated in patient accrual, data analysis, and manuscript writing.*
 50. Steensma DP, Brunner AM, **DeZern AE**, Garcia-Manero G, Komrokji RS, Odenike OS, Roboz GJ, Savona MR, Stone RM, Sekeres MA. Low Clinical Trial Accrual of Patients with Myelodysplastic Syndromes: Causes and Potential Solutions. *Cancer.* 2018;124(24):4601-4609. Epub 2018 Oct 5. PMID: 30289970. *Participated in concept and manuscript writing.*
 51. Alder JK, Hanumanthu VS, Strong MA, **DeZern AE**, Stanley SE, Takemoto CM, Danilova L, Applegate CD, Bolton SG, Mohr DW, Brodsky RA, Casella JF, Greider CW, Jackson JB, Armanios M. Diagnostic utility of telomere length testing in a hospital-based setting. *Proc Natl Acad Sci USA.* 2018;115(10):E2358-E2365. Epub 2018 Feb 20. PMID: 29463765. *Participated in patient accrual, data analysis, and manuscript writing.*
 52. Lau BW, Hu K, Madero-Marroquin R, DeMarchi F, Lim Y, Wang Q, Lobo F, Marchionni L, Smith BD, **DeZern A**, Levis MJ, Aplan PD, Matsui W, Gondek LP. Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity. *Oncogene.* 2019;38(5):687-698. Epub 2018 Aug. 31. PMID: 30171262. *Participated in sample acquisition, data analysis, and manuscript writing.*
 53. Montalban-Bravo G, Kanagal-Shamanna R, Sasake K, Patel K, Ganán-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, **DeZern A**, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. *Blood Adv.* 2019;3(6):922-933. PMID: 30902805. *Participated in study enrollment, manuscript writing and revision.*

54. Savona MR, Odenike O, Amrein PC, Steensma DP, **DeZern AE**, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganessian A, Azab M, Garcia-Manero G. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. *Lancet Haematol.* 2019;6(4):e194-e203. PMID: 30926081. *Participated in patient accrual, data analysis, and manuscript writing.*
55. Sekeres MA, Gore SD, Stablein DM, DeFronzo N, Abel GA, **DeZern AE**, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC, Komrokji RS, Deeq HJ, Epling-Burnette PK. The National History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. *Leuk Lymphoma.* 2019;60(13):3161-3171. Epub 2019 May 21. PMID: 31111762. *Participated in design of study as steering committee member, patient accrual, data analysis, and manuscript writing.*
56. Hambley BC, Norsworthy KJ, Jasem J, Zimmerman JW, Shenderov E, Webster JA, Showel MM, Gondek LP, Dalton WB, Prince G, Gladstone DE, Streiff MB, Pratz KW, Gojo I, Ghiaur G, Levis MJ, Smith BD, **DeZern AE**. Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction. *Leuk Res.* 2019;83:106174. Epub 2019 Jun 21. PMID: 31255938.
57. Gehrie EA, Frank SM, Visagie M, Grabowski MK, Tobian AAR, Strockbine VL, DeMario VM, Lawrence CE, Hambley BC, Ugluk K, Ness PM, **DeZern AE**, Bloch EM. One-unit compared to two-unit platelet transfusions for adult oncology outpatients. *Vox Sang.* 2019;114(5):517-522. Epub 2019 May 5. PMID: 31056742. *Participated in patient accrual, data analysis, and manuscript writing.*
58. Zheng G, Chen P, Pallavajjala A, Haley L, Gondek L, **DeZern A**, Ling H, De Marchi F, Lin MT, Gocke C. The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia. *Am J Hematol.* 2019;94(10):1141. Epub 2019 Aug 7. PMID: 31350794. *Participated in study enrollment, manuscript writing and revision.*
59. Imus PH, Blackford AL, Bettinotti M, Luznik L, Fuchs EJ, Huff CA, Gladstone DE, Ambinder RF, Borrello IM, Fuchs RJ, Swinnen LJ, Wagner-Johnson N, Gocke CB, Ali SA, Bolaños-Meade FJ, Jones RJ, **DeZern AE**. Severe cytokine release syndrome after haploidentical peripheral blood transplantation. *Biol Blood Marrow Transplant.* 2019;25(12):2431-2437. Epub 2019 Aug. 5. PMID: 31394272.
60. Dalton WB, Helmenstine E, Walsh N, Gondek LP, Kelkar DS, Read A, Natrajan R, Christenson ES, Roman B, Das S, Zhao L, Leone RD, Shinn D, Groginski T, Madugundu AK, Patil A, Zabransky DJ, Medford A, Lee J, Cole AJ, Rosen M, Thakar M, Ambinder A, Donaldson J, **DeZern AE**, Cravero K, Chu D, Madero-Marroquin R, Pandey A, Hurley PJ, Luring J, Park B. Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. *J Clin Invest.* 2019;130(11):4708-4723. PMID: 31393856. *Participated in study enrollment, manuscript writing and revision.*
61. Pratz KW, Rudek MA, Smith BD, Karp J, Gojo I, **DeZern A**, Jones RJ, Greer J, Gocke C, Baer MR, Duong VH, Rosner G, Zahurak M, Wright JJ, Emadi A, Levis M. ETCTN-8922 study team. A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation. *Biol Blood Marrow Transplant.* 2020;26(2):300-306. Epub 2019 Sep 21. PMID: 31550496. *Participated in study enrollment, manuscript writing and revision.*
62. Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, **DeZern A**, Roboz G, Garcia-Manero G, Erba H, Ebert BL, Maciejewski JP. Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients with Myelodysplastic Syndromes Using Artificial Intelligence. *JCO Precis Oncol.* 2019;3:10.1200/po.19.00119. Epub 2019 Sep 20. PMID: 31663066. *Participated in study enrollment, manuscript writing and revision.*
63. Zeidner JF, Knaus HA, Zeidan AM, Blackford AL, Montiel-Esparza R, Hackl H, Prince GT, Gondek LP, Ghiaur G, Showel MM, **DeZern AE**, Pratz KW, Smith BD, Levis MJ, Gore S, Coombs CC, Foster MC, Streicher H, Karp JE, Luznik L, Gojo I. Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. *Leukemia.* 2020;34(6):1563-1576. 10.1038/s41375-019-0693-4. Epub 2020 Jan 3. PMID: 31900407.
64. Fenaux P, Platzbecker U, Muftic GJ, Garcia-Manero G, Buckstein R, Santini V, Diez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Gai V, Vyas P, Bowen D, Selleslag Dr, **DeZern AE**, Jurcic JG, Germing U, Gotze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellstrom-Lindberg E, Zeidan AM, Ades L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. *N Engl J Med.* 2020;382(2):140-151. PMID: 31914241. *Participated in study enrollment, manuscript writing and revision.*
65. Schratz KE, Haley L, Danoff SK, Blackford A, **DeZern A**, Gocke CD, Duffield AS, Armanios M. Cancer spectrum and outcomes in the Mendelian short telomere syndromes. *Blood.* 2020;135(22):1946-1956. doi.org/10.1182/blood.2019003264. PMID: 32076714. *Participated in study enrollment, manuscript writing and revision.*

66. Lally K, Kruse RL, Smetana H, Davis R, Roots A, Marshall C, Ness PM, **DeZern AE**, Gladstone DE, Brennan DC, Desai NM, Tobian AAR, Block EM, Gehrie EA. Isohemagglutinin titrating performed on an automated solid-phase and hemagglutinin-based analyzer is comparable to results obtained by manual gel testing. *Transfusion*. 2020;60(3):628-636. Epub 2020 Jan 20. PMID: 31957889. *Participated in study conduct, manuscript writing and revision.*
67. Dalton WB, Helmenstine E, Pieterse L, Li B, Gocke CD, Donaldson J, Xiao Z, Gondek LP, Ghiaur G, Gojo I, Smith BD, Levis MJ, **DeZern AE**. The K666N mutation of SF3B1 is associated with increased progression of MDS and distinct RNA splicing. *Blood Adv*. 2020;4(7):1192-1196. PMID: 32211880.
68. Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, **DeZern A**, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. *Clin Lymphoma Myeloma Leuk*. 2020;S2152-2650(20)30138-5. Doi: 10.1016/j.clml.2020.03.005. Epub ahead of print. PMID: 32303488. *Participated in study enrollment, manuscript writing and revision.*
69. **DeZern AE**, Zahurak ML, Symons HJ, Cooke KR, Rosner G, Gladstone DE, Huff CA, Swinnen LJ, Imus P, Borrello I, Wagner-Johnston N, Ambinder RF, Luznik L, Bolaños-Meade J, Fuchs EJ, Jones RJ, Brodsky RA. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. *Blood Adv*. 2020;4(8):1770-1779. Doi: 10.1181/bloodadvances.2020001729. PMID: 32343796.
70. Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells RA, McCloskey J, Odenike O, **DeZern A**, Yee K, Busque L, O'Connell C, Michaelis LC, Brandwein J, Kantarjian HM, Oganessian A, Azab M, Savona MR. Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamics, randomized, crossover study in MDS and CMML. *Blood*. 2020;136(6):674-683. doi: 10.1182/blood.2019004143. PMID: 32285126. *Participated in study enrollment, manuscript writing and revision.*
71. Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, **DeZern A**, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. *Lancet Haematol*. 2020;7(8):e601-e612. doi: 10.1016/S2352-3026(20)30205-2. Epub 2020 Jun 18. . PMID: 32563283. *Participated in manuscript writing and revision.*
72. Tanasijevic AM, Revette A, Klepin HD, Zeidan A, Townsley D, DiNardo CD, Sebert M, **DeZern AE**, Stone RM, Magnavita ES, Chen R, Sekeres MA, Abel GA. Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. *Leuk Lymphoma*. 2020;15:1-5. Doi:10.1080/10428194.2020.1791854. Epub ahead of print. PMID: 32667230. *Participated in study conduct through expert Delphi panel manuscript writing and revision.*
73. Brierley CK, Zabor EC, Komrokji RS, **DeZern AE**, Roboz GJ, Brunner AM, Stone RM, Sekeres MA, Steensma DP. Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. *Cancer*. 2020. doi: 10.1002/cncr.33105. Epub ahead of print. PMID: 32767690. *Participated in manuscript writing and revision.*
74. **DeZern AE**, Elmariah H, Zahurak M, Rosner GL, Gladstone DE, Ali SA, Huff CA, Swinnen LJ, Imus P, Borrello I, Wagner-Johnston ND, Ambinder RF, Brodsky RA, Cooke K, Luznik L, Fuchs EJ, Bolaños-Meade J, Jones RJ. Shortened-duration immunosuppressive therapy after nonmyeloablative, related HLA-haploidentical or unrelated peripheral blood grafts and post-transplantation cyclophosphamide. *Biol Blood Marrow Transplant*. 2020;26(11):2075-2081. Epub 2020 Aug18. PMID: 32818556.
- a. Awarded 2020 George Santos Award for best clinical science article by a new investigator from American Society for Transplantation and Cellular Therapy
75. Symons HJ, Zahurak M, Cao Y, Chen A, Cooke K, Gamper C, Klein O, Llosa N, Zambidis ET, Ambinder R, Bolaños-Meade J, Borrello I, Brodsky R, **DeZern A**, Gojo I, Showel M, Swinnen L, Smith BD, Luznik L, Jones RJ, Fuchs EJ. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. *Blood Adv*. 2020;4(16):3913-3925. doi: 10.1182/bloodadvances.2020001648. PMID: 32813874. *Participated in study enrollment, manuscript writing and revision.*
76. Imus PH, Tsai HL, **DeZern AE**, Jerde K, Swinnen LJ, Bolaños-Meade J, Luznik L, Fuchs EJ, Wagner-Johnston N, Huff CA, Gladstone DE, Ambinder RF, Gocke CB, Ali SA, Borrello IM, Varadhan R, Brodsky R, Jones RJ. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. *Biol Blood Marrow Transplant*. 2020;19:S1083-8791(20)30575-9. doi: 10.1016/j.bbmt.2020.09.018. Epub ahead of print. PMID: 32961372. *Participated in study enrollment, manuscript writing and revision.*

77. Webster JA, Luznik L, Tsai HL, Imus PH, **DeZern AE**, Pratz KW, Levis MJ, Gojo I, Showel MM, Prince G, Bolaños-Meade J, Gondek LP, Ghiaur G, Dalton WB, Jain T, Fuchs EJ, Gladstone DE, Gocke CB, Ali SA, Huff CA, Borrello IM, Swinnen L, Wagner-Johnston N, Ambinder RF, Jones RJ, Smith BD. Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. *Blood Adv*. 2020;4(20):5078-5088. doi: 10.1182/bloodadvances.2020002945. PMID: 33080006. *Participated in study enrollment, manuscript writing and revision.*
78. Komrokji RS, Al Ali NH, Sallman D, Padron E, **DeZern AE**, Barnard J, Roboz GJ, Garcia-Manero G, List A, Steensma DP, Sekeres MA. Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium. *Cancer Med*. 2020;00:1-7. doi: 10.1002/cam4.3608. Epub ahead of print. PMID: 33350168. *Participated in study enrollment, manuscript writing and revision.*
79. Sallman DA, **DeZern AE**, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbelt G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Eprentapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. *J Clin Oncol*. 2021;10;39(14):1584-1594. doi: 10.1200/JCO.20.02341. Epub 2021 Jan 15. PMID: 33449813. *Participated in study enrollment, manuscript writing, and revision.*
80. **DeZern AE**, Franklin C, Tsai HL, Imus PH, Cooke KR, Varadhan R, Jones RJ. Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. *Blood Adv*. 2021;5(5):1360-1368. doi: 10.1182/bloodadvances.2020003922. PMID: 33661299.
81. Kashanian SM, Li AY, Ali MM, Sutherland ME, Duong VH, Hambley BC, Zacholski K, El Chaer F, Holtzman NG, Imran M, Patzke CL, Cornu J, Duffy A, **DeZern AE**, Gojo I, Norsworthy KJ, Levis MJ, Smith BD, Baer MR, Ghiaur G, Emadi A. Increased body mass index is a risk factor for acute promyelocytic leukemia. *EJHaem*. 2021;(1):33-39. doi: 10.1002/jha2.163. Epub 2021 Jan 6. PMID: 33693438; PMCID: PMC7943182. *Participated in study enrollment, manuscript writing and revision.*
82. Li AY, Kashanian SM, Hambley BC, Zacholski K, Duong VH, El Chaer F, Holtzman NG, Gojo I, Webster JA, Norsworthy KJ, Smith BD, **DeZern AE**, Levis MJ, Baer MR, Kamangar F, Ghiaur G, Emadi A. FLT3-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification. *Biology (Basel)*. 2021;10(3):243. doi: 10.3390/biology10030243. PMID: 33800974. *Participated in study enrollment and manuscript writing.*
83. Sidhom JW, Siddharthan IJ, Lai BS, Luo A, Hambley BC, Bynum J, Duffield AS, Streiff MB, Moliterno AR, Imus P, Gocke CB, Gondek LP, **DeZern AE**, Baras AS, Kickler T, Levis MJ, Shenderov E. Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features. *NPJ Precis Oncol*. 2021 May 14;5(1):38. doi: 10.1038/s41698-021-00179-y. PMID: 33990660. *Participated in case review, manuscript writing and revision.*
84. Karantanos T, Gondek LP, Varadhan R, Moliterno AR, **DeZern AE**, Jones RJ, Jain T. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. *Br J Haematol*. 2021 May 24. doi: 10.1111/bjh.17534. Epub ahead of print. PMID: 34028801. *Participated in manuscript writing.*
85. Venugopal S, Dinardo CD, Takahashi K, Konopleva M, Loghavi S, Borthakur G, **DeZern AE**, Masarova L, Daver NG, Short NJ, Alvarado Y, Ravandi F, Montalban-Bravo G, Sasaki K, Delumpa R, Sekeres MA, Patel BJ, Gail J, Roboz, Kantarjian HM, Garcia-Manero G. Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). *JCO*. 2021;39(15):7010-7010. N DOI: 10.1200/JCO.2021.39.15_suppl.7010. *Participated in study enrollment and manuscript writing.*
86. Zacholski K, Hambley B, Hickey E, Kashanian S, Li A, Baer MR, Duong VH, Newman MJ, **DeZern A**, Gojo I, Smith BD, Levis MJ, Varadhan R, Gehrie E, Emadi A, Ghiaur G. Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia. *J Oncol Pharm Pract*. 2021 Jun 17:10781552211024727. doi: 10.1177/10781552211024727. Epub ahead of print. PMID: 34134554. *Participated in study enrollment and manuscript writing.*
87. Hunter AM, Newman H, **DeZern AE**, Steensma DP, Niyongere S, Roboz GJ, Mo Q, Chan O, Gerds A, Sallman DA, Dominguez-Viqueira W, Letson C, Balasis ME, Ball M, Kruer T, Zhang H, Lancet JE, List AF, Sekeres MA, Komrokji RS, Padron E. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. *Clin Cancer Res*. 2021 Jul 12:clincanres.0935.2021. doi: 10.1158/1078-0432.CCR-21-0935. Epub ahead of print. PMID: 34253584. *Participated in study enrollment, manuscript writing and revision.*
88. Webster JA, Yogarajah M, Zahurak M, Symons H, **DeZern AE**, Gojo I, Prince GT, Morrow J, Jones RJ, Smith BD, Showel M. A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute

- myeloid leukemia (AML) or myelodysplastic syndrome (MDS). *Leuk Lymphoma*. 2021 Jul 21:1-11. doi: 10.1080/10428194.2021.1948029. Epub ahead of print. PMID: 34284701.
89. Rappazzo KC, Zahurak M, Bettinotti M, Ali SA, Ambinder AJ, Bolaños-Meade J, Borrello I, **DeZern AE**, Gladstone D, Gocke C, Fuchs E, Huff CA, Imus PH, Jain T, Luznik L, Rahmat L, Swinnen LJ, Wagner-Johnston N, Jones RJ, Ambinder RF. Nonmyeloablative, HLA-mismatched unrelated peripheral blood transplantation with high-dose posttransplantation cyclophosphamide. *Transplant Cell Ther*. 2021 Aug 20:S2666-6367(21)01162-3. doi: 10.1016/j.jtct.2021.08.013. Epub ahead of print. PMID: 34425261. *Participated in study enrollment, manuscript writing and revision.*
 90. Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, **DeZern AE**, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM. BMT CTN State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. *Transplant Cell Ther*. 2021 Aug 27: S2666-6367(21)01163-5. doi: 10.1016/j.jtct.2021.08.016. Epub ahead of print. PMID: 34461278. *Participated in study enrollment, manuscript writing and revision as CHAIR of non-malignant disease committee for the 2021 SOSS.*
 91. Tschernia NP, Kumar V, Moore DT, Vincent BG, Coombs CC, Van Deventer H, Foster MC, **DeZern AE**, Luznik L, Riches ML, Serody JS, Gojo I, Zeidner JF. Safety and efficacy of pembrolizumab prior to allogeneic stem cell transplant in Acute Myeloid Leukemia. *Transplant Cell Ther*. 2021 Aug 30:S2666-6367(21)01171-4. doi: 10.1016/j.jtct.2021.08.022. Epub ahead of print. PMID: 34474164. *Participated in study enrollment, manuscript writing and revision.*
 92. Carraway HE, Sawalha Y, Gojo I, Lee MJ, Lee S, Tomita Y, Yuno A, Greer J, Smith BD, Pratz KW, Levis MJ, Gore SD, Ghosh N, **DeZern A**, Blackford AL, Baer MR, Gore L, Piekarz R, Trepel JB, Karp JE. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. *Leuk Res*. 2021 Sep 10;110:106707. doi: 10.1016/j.leukres.2021.106707. Epub ahead of print. PMID: 34563945. *Participated in study enrollment, manuscript writing and revision.*
 93. Ambinder A, Smith M, Tsai HL, Varadhan R, **DeZern A**, Dalton W, Gocke C, Webster J, Gondek L, Gojo I, Ali SA, Huff CA, Swinnen L, Wagner-Johnston N, Showel M, Prince G, Borrello I, Bolanos-Meade J, Luznik L, Jain T, Imus P, Fuchs E, Ambinder R, Gladstone DE, Levis M, Jones R, Ghiaur G, Smith BD. Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia with IDH Mutations: A Single Center Experience. *Clinical Lymphoma Myeloma and Leukemia*. 2021 Oct doi.org/10.1016/j.clml.2021.09.022. Epub ahead of print. *Participated in study enrollment, manuscript writing and revision.*
 94. Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A, Iqbal M, Grunwald MR, Dholaria B, Elmariah H, Ozga M, Singh A, Abedin S, **DeZern AE**, Jones RJ, Gupta V, Gerds AT, Jain T. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. *Leukemia*. 2021 Oct 18. doi: 10.1038/s41375-021-01449-1. Epub ahead of print. PMID: 34663912. *Participated in manuscript writing and revision.*
 95. Gerber GF, **DeZern AE**, Chaturvedi S, Brodsky RA. A 15-year, single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinuria patients on terminal complement inhibition with history of thromboembolism. *Am J Hematol*. 2021 Nov 20. doi: 10.1002/ajh.26414. Epub ahead of print. PMID: 34800310. *Participated in study enrollment, manuscript writing and revision.*
 96. Gibson CJ, Kim HT, Zhao L, Murdock HM, Hambley B, Ogata A, Madero-Marroquin R, Wang S, Green L, Fleharty M, Dougan T, Cheng CA, Blumenstiel B, Cibulskis C, Tsuji J, Duran M, Gocke CD, Antin JH, Nikiforow S, **DeZern AE**, Chen YB, Ho VT, Jones RJ, Lennon NJ, Walt DR, Ritz J, Soiffer RJ, Gondek LP, Lindsley RC. Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. *J Clin Oncol*. 2022 Jan 10;40(2):189-201. doi: 10.1200/JCO.21.02286. Epub 2021 Nov 18. PMID: 34793200; PMCID: PMC8718176. *Participated in study enrollment, manuscript writing and revision.*
 97. Zeidner JF, Vincent BG, Ivanova A, Moore D, McKinnon KP, Wilkinson AD, Mukhopadhyay R, Mazziotta F, Knaus HA, Foster MC, Coombs CC, Jamieson K, Van Deventer H, Webster JA, Prince GT, **DeZern AE**, Smith BD, Levis MJ, Montgomery ND, Luznik L, Serody JS, Gojo I. Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. *Blood Cancer Discov*. 2021 Sep 10;2(6):616-629. doi: 10.1158/2643-3230.BCD-21-0070. PMID: 34778801; PMCID: PMC8580622. *Participated in study enrollment, manuscript writing and revision.*
 98. Jain T, Tsai HL, **DeZern AE**, Gondek LP, Elmariah H, Bolaños-Meade J, Luznik L, Fuchs E, Ambinder R, Gladstone DE, Imus P, Webster J, Prince G, Ghiaur G, Smith BD, Ali SA, Ambinder A, Dalton WB, Gocke CB, Huff CA, Gojo I, Swinnen L, Wagner-Johnston N, Borrello I, Varadhan R, Levis M, Jones RJ. Posttransplantation Cyclophosphamide-based Graft versus Host Disease Prophylaxis with Non-myeloablative Conditioning for Blood

- or Marrow Transplantation for Myelofibrosis. *Transplant Cell Ther.* 2022 Feb 11:S2666-6367(22)00059-8. doi: 10.1016/j.jtct.2022.02.004. Epub ahead of print. PMID: 35158092. *Participated in study enrollment, manuscript writing and revision.*
99. Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, Santini V, Díez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, **DeZern AE**, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, Verma A. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. *Leukemia.* 2022 Feb 26. doi: 10.1038/s41375-022-01521-4. Epub ahead of print. PMID: 35220402. *Participated in study enrollment, manuscript writing and revision.*
 100. Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A, Iqbal M, Grunwald MR, Dholaria B, Elmariah H, Ozga M, Singh A, Abedin S, **DeZern AE**, Jones RJ, Gupta V, Gerds AT, Jain T. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. *Leukemia.* 2022 Mar;36(3):856-864. doi: 10.1038/s41375-021-01449-1. Epub 2021 Oct 18. PMID: 34663912.
 101. Karantanos T, Tsai HL, Gondek LP, **DeZern AE**, Ghiaur G, Dalton WB, Gojo I, Prince GT, Webster J, Ambinder A, Smith BD, Levis MJ, Varadhan R, Jones RJ, Jain T. Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. *Leuk Lymphoma.* 2022 Apr 4:1-7. doi: 10.1080/10428194.2022.2057488. Epub ahead of print. PMID: 35379077.
 102. Jain T, Tsai HL, **DeZern AE**, Gondek LP, Elmariah H, Bolaños-Meade J, Luznik L, Fuchs E, Ambinder R, Gladstone DE, Imus P, Webster J, Prince G, Ghiaur G, Smith BD, Ali SA, Ambinder A, Dalton WB, Gocke CB, Huff CA, Gojo I, Swinnen L, Wagner-Johnston N, Borrello I, Varadhan R, Levis M, Jones RJ. Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. *Transplant Cell Ther.* 2022 May;28(5):259.e1-259.e11. doi: 10.1016/j.jtct.2022.02.004. Epub 2022 Feb 11. PMID: 35158092; PMCID: PMC9081210.

HOW LOW RISK ARE LOW RISK

Review Articles

1. **DeZern AE**, Brodsky RA. Clinical management of aplastic anemia. *Expert Rev Hematol.* 2011;4(2):221-30. Review. PMID: 21495931.
2. **DeZern AE**, Guinan EC. Therapy for aplastic anemia. *Hematology Am Soc Hematol Educ Program.* 2011:82-3. PMID: 22160016.
3. **DeZern AE**, Guinan EC. Aplastic Anemia in Adolescents and Young Adults. *Acta Haematol.* 2014;132(3-4):331-9. Epub 2014 Sep 10. PMID: 25228559.
4. **DeZern AE**, Sekeres MA. The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure. *Oncologist.* 2014;19(7):735-45. Epub 2014 Jun 4. PMID: 24899643.
5. **Gondek LP**, **DeZern AE**. I Walk the Line: How to Tell MDS From Other Bone Marrow Failure Conditions. *Curr Hematol Malign Rep.* 2014;9(4):389-99. PMID: 25079655.
6. **DeZern AE**, Brodsky RA. Paroxysmal Nocturnal Hemoglobinuria: A Complement-Mediated Hemolytic Anemia. *Hematol Oncol Clin North Am.* 2015;29(3):479-494. PMID: 26043387.
7. **DeZern AE**. Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse? *Hematology Am Soc Hematol Educ Program.* 2015;2015:308-16. PMID: 26637738.
8. Schroeder MA, **DeZern AE**. Do somatic mutations in de novo MDS predict for response to treatment? *Hematology Am Soc Hematol Educ Program.* 2015;2015:317-28. PMID: 26637739.
9. Hill A, **DeZern AE**, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. *Nat Rev Dis Primers.* 2017 May 18;3:17028. Doi: 10.1038/nrdp.2017.28. PMID: 28516949.
10. **DeZern AE**, Brodsky RA. Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia. *Hematol Oncol Clin North Am.* 2018 Aug;32(4):629-642. doi: 10.1016/j.hoc.2018.04.001. Epub 2018 May 28. PMID: 30047416.
11. **DeZern AE**. Treatments Targeting MDS Genetics: A Fool's Errand? *Hematology Am Soc Hematol Educ Program.* 2018 Nov 30;2018(1):277-285. Doi: 10.1182/asheducation-2018.1.277. PMID: 30504322 PMCID: PMC6246001.
12. **DeZern AE**, Malcovati L, Ebert BL. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice. *Am Soc Clin Oncol Educ Book.* 2019 Jan;(39):400-410. Doi: 10.1200/EDBK_239083. Epub 2019 May 17. PMID: 31099654.
13. Elmariah H, **DeZern AE**. Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment. *Curr Hematol Malign Rep.* 2019 Jun;14(3):154-163. . Doi: 10.1007/s11899-019-00509-9. Review. PMID: 31093889.
14. Schratz KE, **DeZern AE**. Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice. *Hematol/Oncol*

- clin N Am.* 2020 April;34(2):333-356. Epub 2020 Jan 6. PMID: 32089214.
15. Ambinder A., Miller J, **DeZern AE**. Autoimmune disease in CMML- The chicken or the egg? *Best Practice & Research: Clinical Haematology.* 2020 Jun;33(2):101136. doi: 10.1016/j.beha.2019.101136. Epub 2019 Dec 17. PMID: 32460986.
 16. **DeZern AE**, Gondek LP. Stem cell donors should be screened for CHIP. *Blood Adv.* 2020 Feb 25;4(4):784-788. PMID: 32097458.
 17. Karantanos T, Jain T, Moliterno AR, Jones RJ, **DeZern AE**. Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology. *Int J Mol Sci.* 2021 Mar 5;22(5):2595. doi: 10.3390/ijms22052595. PMID: 33807519.
 18. **DeZern AE**, Churpek JE. Approach to the diagnosis of aplastic anemia. *Blood Adv.* 2021 Jun 22;5(12):2660-2671. doi: 10.1182/bloodadvances.2021004345. PMID: 34156438.
 19. Karantanos T, **DeZern AE**. Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome. *Best Practice & Research: Clinical Haematology.* 2021 Jun 26. doi.org/10.1016/j.beha.2021.101280.
 20. **DeZern AE**, Dalton WB. How low risk are low risk myelodysplastic syndromes? *Expert Rev Hematol.* 2022 Jan 18. doi: 10.1080/17474086.2022.2029698. Epub ahead of print. PMID: 35041576.
 21. Richardson DR, **DeZern AE**. Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS? *Hematology Am Soc hematol Educ Progra.* 2021(1):435-438.
 22. **DeZern AE**. Lower risk but high risk. *Hematology Am Soc Hematol Educ Program.* 2021 Dec 10;2021(1):428-434. doi: 10.1182/hematology.2021000277. PMID: 34889376; PMCID: PMC8791100.

Consensus Publications

1. Myelodysplastic syndromes, version 2.2015. Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, **DeZern AE**, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C. *J Natl Compr Canc Netw.* 2015;13(3):261-72.
2. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, DeCastro CM, Deeg HJ, **DeZern AE**, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C. *J Natl Compr Canc Netw.* 2017;15(1):60-87.
3. Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, **DeZern AE**, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. *J Natl Compr Canc Netw.* 2022 Feb;20(2):106-117. doi: 10.6004/jnccn.2022.0009. PMID: 35130502.

Case Reports

1. Gaillard S, Dinoso JB, Marsh JA, **DeZern AE**, O'Connell KA, Spivak AM, Alwood K, Durand CM, Ambinder RF, Blankson JN. Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. *J Clin Virol.* 2011;51(3):195-8.
2. Zeidan AM, Mitchell M, Khatri R, Itani D, Boikos S, Bose S, Lipsett P, Efron D, King KE, Gerber J, **DeZern A**. Spontaneous Splenic Rupture during Induction Chemotherapy for Acute Myeloid Leukemia. *Leuk Lymphoma.* 2014;55(1):209-12.

Textbook Chapters

1. Le T, Bhushan V, Dierberg K, Grow R, **DeZern A**, Calvello E, Mathelier H. First Aid for the USMLE Step 2: Clinical Knowledge, 4th Ed. New York: McGraw-Hill Professional; London: McGraw-Hill, 2006.
2. **DeZern A**, Huff C. Plasma Cell Dyscrasias. Johns Hopkins Internal Medicine Board Review 2010-2011, 3rd Ed. Philadelphia: Mosby Elsevier.
3. Scheinberg P, **DeZern AE**, Steensma DP. Acquired marrow failure syndromes: aplastic anemia, paroxysmal nocturnal hemoglobinuria, and myelodysplastic syndromes. In: Cuker A, Steensma DP, Kempton CL, Nowakowski GS (eds). ASH-SAP American Society of Hematology Self-Assessment Program. 6th Ed. Washington DC: American Society of Hematology; 2016:489-520.

4. Duffield A, **DeZern A**. Textbook of Uncommon Cancer, 5th Ed. Raghavan D, Ahluwalia M, Blanke CD, Brown J, Kim ES, Reaman GH, Sekeres MA (eds). 2017; John Wiley/Sons Ltd Publ. Sec 8: Hematological Malignancies. 46 Rare Bone Marrow Failure Conditions. *Textbook of Uncommon Cancer*. Derek Raghavan D *et al* (ed). 2017
5. **DeZern A**, Brodsky R. Wintrobe's Hematology, 14th Ed. Chapter on Acquired Aplastic Anemia. 2018:2968-3003.
6. Smith C, **DeZern AE**. Acquired marrow failure syndromes: aplastic anemia, paroxysmal nocturnal hemoglobinuria, and myelodysplastic syndromes. In: Cuker A, Steensma DP, Kempton CL, Nowakowski GS (eds). ASH-SAP American Society of Hematology Self-Assessment Program. 7th Ed. Washington DC: American Society of Hematology; 2019:546-579.
7. **DeZern AE**, Brodsky RA. Aplastic Anemia and Related Bone Marrow Failure States, In: *27th Edition of Goldman-Cecil Medicine*. 2022: pages pending.
8. **DeZern A**, Brodsky R. Wintrobe's Hematology, 15th Ed. Chapter on Acquired Aplastic Anemia. 2022: pages pending.

Books

1. **DeZern A**. Aplastic Anemia. 2018 Ed, Conn's Current Therapy. In *Diagnosis and Management of Myelodysplastic Syndromes: A Clinical Guide*. 2018
2. **DeZern AE**, Hambley B. Treatment algorithms for higher-risk disease. In: *Diagnosis and Management of Myelodysplastic Syndromes: A Clinical Guide*. Aug 2019.

Editorials

1. **DeZern AE**, Brodsky RA. Genetic panels in young patients with bone marrow failure: are they clinically relevant? *Haematologica*. 2016;101(11):1275-1276.
2. Gondek L, **DeZern AE**. Assessing Clonal Hematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states. *Lancet Haematology*. 2020 Jan;7(1):e73-e81. doi: 10.1016/S2352-3026(19)30211-X. Epub 2019 Dec 3. PMID: 31810765.
3. Jain T, **DeZern AE**. Why hurry up and wait? Transplantation in Lower Risk MDS. *Biol Blood Marrow Transplant*. 2020;26(11):e263-e264. doi: 10.1016/j.bbmt.2020.09.012. Epub 2020 Sep 19. PMID: 32961368.
4. **DeZern AE**. Relevant metrics: how significant CCUS truly is. *Blood*. 2021 Sep 16;138(11):918-919. doi: 10.1182/blood.2021013088. PMID: 34529016.
5. Figueroa ME, **DeZern AE**. Editorial: Advancing Science for Clinical Care in MDS. *Front Oncol*. 2022 Apr 21;12:901118. doi: 10.3389/fonc.2022.901118. PMID: 35530304; PMCID: PMC9068944.

Other Media

- 8/13 Aplastic Anemia Webinar, Aplastic Anemia Myelodysplastic Syndrome International Foundation education series, www.aamds.org
- 3/16 Paroxysmal Nocturnal Hemoglobinuria 101 Webinar, Aplastic Anemia Myelodysplastic Syndrome International Foundation education series, www.aamds.org
- 8/16 Paroxysmal Nocturnal Hemoglobinuria, www.dynamed.com
- 8/16 Aplastic Anemia, www.dynamed.com
- 1/17 National Organization for Rare Disorders, (NORD) Acute Myeloid Leukemia for Providers, www.rarediseases.org
- 2/19 A New Standard Emerges: Rational Use of Venetoclax to Inhibit BCL-2 Allows Treatment of AML In Older Patients. **Dr. DeZern** discusses two studies that show improved outcomes for older patients with AML using a venetoclax and hypomethylating agents combination. <https://doi.org/10.1182/hem.V16.2.9382>.
- 4/19 Thrombocytopenia Post-transplantation: A Clinical Challenge in Need of a Therapy. **DeZern** reviews two manuscripts observing the clinical experience of eltrombopag for thrombocytopenia post-stem cell transplantation. <https://doi.org/10.1182/hem.V16.3.9512>.
- 5/19 Should We Utilize Maintenance Therapy Post-Hematopoietic Cell Transplantation in Patients With FLT3/ITD-positive AML? **Dr. DeZern** comments on a study in which adult patients with FLT3/ITD acute myeloid leukemia are randomized to receive gilteritinib or placebo after the time of engraftment for a two-year period. <https://doi.org/10.1182/hem.V16.4.9638>.
- 7/19 Compelling Evidence for Targeted Immunotherapy As Treatment for AML. Drs. Kagan and **DeZern** discuss a novel approach to acute myeloid leukemia, particularly in the relapsed setting, that utilizes CD33-targeted CAR-Ts or antibody-drug conjugates coupled with transplantation of engineered stem cells to protect normal hematopoiesis. <https://doi.org/10.1182/hem.V16.5.9779>.
- 9/19 Does Your MDS Treatment Have Mettle? The Utility of Iron Chelation Is Always A Point of Discussion in MDS. **Dr. DeZern** discusses the utility of iron chelation therapy in myelodysplastic syndromes. <https://doi.org/10.1182/hem.V16.6.9910>.

- 11/19 Figure 1: (Website learning tool) A diagnostic approach to a patient with pancytopenia
- 12/19 2019 Brings Biologic Understanding and Hope for Patients with TP53 Mutated Myelodysplastic Syndrome **Drs. DeZern** and Karantanos share exciting findings in the biologic understanding of TP53-mutated myelodysplastic syndromes which allow for future refinement to current therapeutic algorithms. <https://doi.org/10.1182/hem.V17.1.10133>.
- 2/20 Identification of Malignant Cell Populations Years Before Development of Treatment-related Leukemia in Patients with Myeloma. Dr. **DeZern** discusses a study that shows stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. <https://doi.org/10.1182/hem.V17.2.10253>.
- 3/20 Can Leuk-warm Be Hot? Heating Up the Debate of Non-canonical Hotspot Spliceosomal Mutations in Myeloid Pathogenesis. **Dr. DeZern** reviews how "hotspot" spliceosomal mutations drive myeloid disease pathogenesis with an increased risk of transformation to acute leukemia. <https://doi.org/10.1182/hem.V17.3.10321>.
- 6/20 CHIPS-A-LOY Loss of Chromosome Y Clusters With CHIP-associated Mutations. **Dr. DeZern** discusses the relationship between loss of the Y chromosome and clonal hematopoiesis. <https://doi.org/10.1182/hem.V17.4.12884901909>.
- 8/20 Variant CURation: A Key Clinical Need Toward CUREs in Patients with Inherited Predisposition. **Dr. DeZern** discusses RUNX1 FPD/AML variant curation. <https://ashpublications.org/thehematologist/article/464053>.
- 11/20 Safe Tension: What the Latest Data Say About Waiting to Induce in AML. **Dr. DeZern** discusses the timing of induction therapy in AML. <https://ashpublications.org/thehematologist/article/464083>.
- 12/20 Big Questions in 2020: Single-cell Sequencing in Myeloid Malignancies Brings Us Closer to Answers. **Dr. DeZern** reviews deeper dive into clonality with novel techniques. <https://ashpublications.org/thehematologist/article/474708>/ Big-Questions-in-2020-Single-cell-Sequencing-in
- 2/21 Short-term Gain but Long-term Pain? Clonal Hematopoiesis and the Risk of Therapy-related Myeloid Neoplasms After Treatment for Solid Tumors. **Dr. DeZern** discusses the effect of chemotherapy for solid tumors which could lead to later myeloid malignancies. [ashpublications.org/thehematologist...erm-Pain-Clonal](https://ashpublications.org/thehematologist/article/474708).
- 2/21 Interviewer, The Hematologist Podcast, Dr DeZern interviews Dr. Bolton about above paper.
- 3/21 Can We "Go with the Flow?" Drs. Kagan and **DeZern** discuss analysis of decentralized measurable residual disease assessment by flow cytometry in AML. [https://ashpublications.org/thehematologist/article/475636/Can-We-Go-with-the-Flow?](https://ashpublications.org/thehematologist/article/475636)
- 6/21 Please "Eat me": Can Magrolimab Put Higher-risk MDS Back on the Immunologic Menu? Drs. Marple and **DeZern** review this open Phase III clinical trial of magrolimab in combination with azacytidine compared to azacytidine alone. <https://doi.org/10.1177/10781552211024727>.
- 8/21 Release More Inhibitions? Pegcetacoplan Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria. Gerber GF, **DeZern A**. [ashpublications.org/thehematologist/article](https://ashpublications.org/thehematologist/article/475636) (2021);18 (5). <https://doi.org/10.1182/hem.V18.5.202151>.
- 10/21 Older Patients with High Risk MDS Benefit from Allogeneic Transplant. Hochman MR, **DeZern A**. <https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V18.6.202161/477244/Older-Patients-With-High-Risk-MDS-Benefit-From>. Dr. DeZern reviews two recent trials utilizing BMT in older adults with MDS.
- 10/21 Severe Aplastic Anemia: Approach to Diagnosis. <https://www.vumedi.com/video/severe-aplastic-anemia-approach-to-diagnosis/>; Dr. DeZern discusses how best to diagnosis this marrow failure syndrome.
- 10/21 Severe Aplastic Anemia: Current Advances. <https://www.vumedi.com/video/severe-aplastic-anemia-current-advances/>; Dr. DeZern reviews the latest data on therapeutics for this marrow failure syndrome.
- 12/21 Battle of the clones: somatic genetic rescue of pediatric MDS patients teaches us about MDS biology in 2021 and a platform for the future. **DeZern A**. <https://ashpublications.org/thehematologist/article>. Dr. DeZern reviews seminal paper from Nature Medicine in 2021 about somatic gene rescue in the bone marrow failure state of SAMD9 and SAMD9L.
- 12/21 Managing MDS in the wake of a global pandemic. *MDS Foundation Fall/Winter Newsletter*. 2021.

FUNDING

EXTRAMURAL Funding

Research Extramural Funding- Current

- 4/15/14-12/31/21 A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study

	<p>Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity MCC-17259 Incyte / Moffitt Clinical Research Network \$78,380 Role: PI: 1%</p>
8/1/16-7/31/23	<p>A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine versus Single-Agent Azacitidine in Patients with Higher-Risk Myelodysplastic. Pevonedistat-2001 Millennium Pharmaceuticals \$439,056 Role: PI: 1%</p>
10/7/16-10/6/21	<p>A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (Ace-536) Versus Placebo for the Treatment of Anemia Due to Ipss-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects with Ring Sideroblasts Who Require Red Blood Cell Transfusions the “Medalist” Trial. ACE-536-MDS-001 Celgene Corporation \$363,366 Role: PI: 1%</p>
6/2/17-04/30/23	<p>Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (CHAMP) [BMT CTN 1502]. 90071718 National Marrow Donor Program \$162,853 Role: PI: 1%</p>
8/1/17-6/30/22	<p>A Phase 2 Study of Tipifarnib in Subjects with Chronic Myelomonocytic Leukemia. KO-TIP-004 Kura Oncology \$371,986 Role: PI: 1%</p>
12/11/17-12/10/21	<p>A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination with Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms. 90076399 H Lee Moffitt Cancer Center \$98,452 Role: PI: 1%</p>
11/1/18-10/31/23	<p>Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia. 90080971 Astex \$315,059 Role: PI: 1%</p>
11/1/18-10/14/23	<p>Targeted therapy with the mutant IDH2-inhibitor enasidenib (AG221) for high-risk IDH2-mutant myelodysplastic syndrome. 90080971 MD Anderson (Celgene) \$77,600 Role: PI: 1%</p>

4/1/19-2/25/23	<p>A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence after Decitabine in Patients with Myelodysplastic Syndromes (MDS).</p> <p>TPI-AVLV Tolero \$417,810 Role: PI: 1%</p>
5/6/19-5/5/23	<p>A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.</p> <p>The primary objective of this study is to evaluate the safety and pharmacokinetics (PK) of orally administered PLX2853 as a single agent in subjects with relapsed or refractory AML or high-risk MDS.</p> <p>PLX124-02 Plexxikon \$264,017 Role: PI: 1%</p>
9/30/19-9/29/24	<p>An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727</p> <p>ASTEX27-06 Astex \$139,673 Role: PI: 1%</p>
10/22/19-10/21/24	<p>Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes</p> <p>A19-11172 Aprea \$421,569 Role: PI: 1%</p>
1/10/20-1/09/24	<p>Phase II Trial of APR-246 in Combination with Azacitidine as Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplant</p> <p>A18-015331 Aprea \$264,017 Role: PI: 1%</p>
8/1/20-11/30/23	<p>A Novel Cell-based Immunotherapy for the Treatment of Patients with Myelodysplastic Syndrome (MDS) Directed against CD123.</p> <p>EvansMDS Edward P. Evans Foundation \$600,000 Role: PI: 10%</p>
8/5/20-8/4/25	<p>Sequential Two-Stage Dose Escalation Study to Evaluate to Evaluate the Safety and Efficacy of Ruxolitinib for the treatment of Chronic Myelomonocytic Leukemia (CMML): Phase 2 Expansion to determine the safe and recommended Phase 2 dose (RP2D) of APR-246 in combination with azacitidine as determined by dose-limiting toxicities (DLTs). The main goal of this study is to evaluate the safety and tolerability of ruxolitinib in CMML subjects at diagnosis or relapse.</p> <p>90090862 H Lee Moffitt Cancer Center \$141,606 Role: PI: 1%</p>

- 1/1/21-12/31/25 Modeling Myelodysplasia. The major goal of this project is to validate the humanized xenograft-recipient mouse model by single-cell genetic and genomic characterization of diagnostic MDS patient material before therapy and of the same cells engrafted in humanized mice, clearly delineating the transcriptional impact of xenografting. Next, we will establish pharmacodynamic endpoints for aza within the mouse model and apply the empirically derived dose of aza to the model. Human MDS material will be captured for single cell analyses post-aza therapy from both patients and xenografts.
R01 CA253981
NIH
\$491,251
PI: Grimes
Role: Co-Investigator: 5%
- 9/20/21-8/31/22 Biologic and Therapeutic Consequences of Distinct Hotspot SF3B1 Mutations in MDS. The major goal of this project is to characterize the landscape of private and shared JEMs among hotspot SF3B1 mutations in MDS and to establish the role of distinct SF3B1 mutations in the growth and differentiation of human hematopoietic cells.
1R56HL 159306-01
NIH
\$409,375
PI: Dalton
Role: Co-Investigator: 10%
- 10/1/21-9/30/24 Therapeutic modulation of serine availability for SF3B1-mutant myeloid malignancies. The major goals are to determine the preclinical therapeutic impact of pCBS in SF3B1-mutant myeloid malignancies and to characterize the RNA missplicing mechanisms that sensitize SF3B1-mutant cells to serine restriction.
LLS TRP 2021
LLS
\$600,000
PI: Dalton
Role: Co-Investigator: 2%
- 4/1/22-3/31/27 Biologic and Therapeutic Consequences of Distinct Hotspot SF3B1 Mutations in MDS. The major goals of this project are to 1) Characterize the landscape of shared and private RNA missplicing events among hotspot SF3B1 mutations in MDS; 2) Establish the role of distinct SF3B1 mutations in the growth and differentiation of human hematopoietic cells; and 3) Define the clinicopathologic features of distinct SF3B1 mutations in MDS.
R01 HL159306-01A1
NIH
\$2,046,875
Role: PI: 10% (multi PI with William B Dalton, MD, PhD)

Research Extramural Funding – Pending None

Research Extramural Funding - Previous

- 5/31/13-10/31/19 An open-label, randomized, Phase 2, parallel, dose-ranging, multicenter, study of sotatercept for the treatment of patients with anemia and low- or intermediate-1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leukemia (CMML).
ACE-011-MDS-001
Celgene Corporation
\$155,458
Role: PI: 1%
- 9/1/13 – 8/31/14 Pilot and Feasibility Study of Restrictive Red Cell Transfusion Goal in Patients with Acute leukemias.

90057302
Society for the Advancement of Blood Management
\$20,000
Role: PI: 5%

1/16/14-11/30/18 A Phase II Randomized, Double-Blinded, Placebo-Controlled Study of Pracinostat in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk 2 or High-Risk Myelodysplastic Syndrome (MDS).
MDS#14
Sarah Cannon Research Institute/ AAMDS
\$216,922
Role: PI: 1%

6/17/14 – 12/31/19 MDS Clinical Research Consortium
90056518 MDS Supplement
Aplastic Anemia and MDS International Foundation
\$270,000
Role: PI: 10%

8/1/14-4/30/18 Advancing Diagnostics and Therapeutics in Bone Marrow Failure.
1 K23 HL123601-01
NIH
\$130,874
Role: PI: 75%

2/25/15-11/12/16 A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia due to IPSS Lower-risk Myelodysplastic Syndromes.
AZA-MDS-003
Celgene Corporation
\$295,642
Role: PI: 1%

3/26/15-12/31/19 A Phase 1-2 Pharmacokinetic Guided Dose-escalation and dose-confirmation study of ASTX727, a combination of the oral cytidine deaminase inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with MDS.
ASTX727-01
Astex
\$258,505
Role: PI: 1%

4/16/15-12/31/19 A Randomized, double-blinded phase 1B/2 Study of PF-04449913 in Combination with Azacitidine in Patients with Previously Untreated Intermediate-2 or High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia with 20-30% Blasts and Multi-lineage Dysplasia, or Chronic Myelomonocytic Leukemia [B1371012]
To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of PF-04449913 in combination with low dose Ara-C (LDAC; Arm A), decitabine (Arm B) or cytarabine/daunorubicin (Arm C) when administered to adults with previously untreated AML or high-risk MDS.
B1371012
Pfizer Incorporated
\$399,996
Role: Co-PI: 1%

12/15/15-12/18/19 A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).

CC-486-GEN-001
Celgene Corporation
\$34,824
Role: PI: 1%

7/1/16 – 12/31/18 Regenerative Medicine to Restore Normal Hematopoiesis in Aplastic Anemia.
2016-MSCRFE-2622
Maryland Stem Cell Research Fund (TEDCO)
\$100,000
Role: PI: 2%

9/27/17-7/31/19 Advancing Diagnostics and Therapeutics in Bone Marrow Failure.
1R03HL136797-01
National Heart, Lung, and Blood Institute
\$50,000
Role: PI: 10%

5/1/18-4/30/20 Cancer Clinical Investigator Team Leadership Award for Fiscal Year (FY) 18.
P30CA006973
NCI
\$61,068
PI: Nelson
Role: Co-PI: 14%

Research Intramural Funding - Current

1/31/20-12/31/22 Hematologic Malignancies and Bone Marrow Transplantation (HMBMT) CCSG Program
80052098
SKCCC
\$150,000
PI: Gondek
Role: Co-PI: 5%

Research Intramural Funding – Pending None

Research Intramural Funding – Previous None

CLINICAL ACTIVITIES

Clinical Focus

- Care of patients with marrow failure syndromes including aplastic anemia and myelodysplastic syndrome as well as their clonal evolution to paroxysmal nocturnal hemoglobinuria or acute leukemia
- Manage patients through all stages of diagnosis and therapy with both standard of care treatments and on clinical trials.

Certification

2005-present Advanced Cardiac Life Support
2009 American Board of Internal Medicine - Internal Medicine
2013 American Board of Internal Medicine - Hematology
Eligible American Board of Internal Medicine – Medical Oncology

Licensure

2009 Maryland Board of Physicians (D0067193)
2009 Maryland CDS (M64474)
2009 DEA Registration (FD0753663)
2021 Commonwealth of Pennsylvania Medical Physician (MD476029)
2021 Commonwealth of Virginia Department of Health Professions (0101272927)

Clinical Service Responsibilities

2012-present Hematologic Malignancies, Inpatient Services, 8 weeks/year
2012-present Hematologic Malignancies, Outpatient Services, 1.5 day/week

2012-present Bone Marrow Reader, 6 weeks/year
 2012-present Fellow Supervision: Myeloid Disorders Clinic, 2 days/month
 2012-present Fellow Supervision: Longitudinal Clinic, 1 day/month

Clinical Productivity

2013-present Dr. DeZern has performed at high clinical level with 1008-1865 outpatient RVUs and 1708-2592 inpatient RVUs .

Clinical Draw

Dr. DeZern sees approximately 120 new patients yearly as well as follows nearly another 200 follow up patients each year. (FY21 964 patient encounters, 116 of these new patients) Many in-state and out of state referrals come directly to Dr. DeZern for a second opinion on bone marrow failure as well as the specific goal of being treated at Hopkins on an AA or MDS clinical trial for which Dr. DeZern is the PI. Twenty-three states are represented in Dr. DeZern’s patient population (51% out-of state new patient visits).

Membership in or examiner for specialty board None

Clinical Program Building / Leadership

2011- present: Development of the Johns Hopkins Center for Bone Marrow Failure with maintenance of database, clinical trial portfolio and increase in patient referrals since 2012 appointment

- 2011- present: 120 patients/ year seen for MDS referrals (increased over 2007-2011:75 new MDS patients/ year)
- 13 clinical trials open in MDS over previous 14 years (about 10-15 MDS patients enrolled yearly)
- Active recruitment from the outside
- Total MDS trials opened= 23
- Increased volume of patients put on clinical trial for MDS per year- total FY19 46 (not including BMT trials)

2020-present Chair of the Independent Data Monitoring Committee (IDMC) for the IMerge Phase 3 study in MDS

Clinical Demonstration Activities None

Development of nationally/internationally recognized clinical standard of care None

EDUCATIONAL ACTIVITIES

Teaching

Classroom instruction

JHMI/Regional

2011-present Medical Student Instructor for Hematology-Oncology Curriculum of Genes to Society, Johns Hopkins School of Medicine
 2012-present Medical Oncology Fellows Communication Workshop
 2013-present Medical Oncology Fellowship Lecture Course. *Myelodysplastic Syndromes*
 2013-present Fellow Oncology Multidisciplinary Teaching Conference Co-coordinator, Johns Hopkins University (Myeloid Conference)
 2014- present Barker Firm Faculty for the Osler Medical service
 2019- present Myeloid Conference Organizer

National

2022 Highlights of American Society of Hematology, Washington, DC. (Chair)
 2022 Highlights of American Society of Hematology, Dallas, TX. (Chair)

International

2016 IV Ibero-American Symposium on Myelodysplastic Syndrome, Puerto Vallarta, Mexico (Faculty)
 2017 American Society of Hematology Clinical Research Training Institute, Uruguay (Faculty)
 2021 Highlights of American Society of Hematology, Mexico (Faculty)
 2022 Highlights of American Society of Hematology in Latin America, Iguazu Falls (Faculty)

Clinical instruction

JHMI/Regional

2009-2010 Clinical skills instruction for internal medicine residents and medical student on the Janeway Medical Service

2011-present Clinical skills instruction for internal medicine residents and medical oncology fellows on the Leukemia Inpatient Service (SKCCC)

2011-present Clinical skills instruction for medical oncology fellows on the Hemato-Oncology Consult Service (JHH) and the Medical Oncology Outpatient Department (SKCCC)

2014-present Housestaff teaching on the Barker Firm of the Osler Medical service.

National None

International None

CME instruction Please see Invited Talks Section

Mentoring

Predoctoral

2015-2017 Katherine Williams, MS2- Scholarly Concentrations; focus on transfusional support in acute leukemia and impact on patient quality of life (now applying for oncology fellowships)

2018-2019 Dylan Hardenbergh, MS2- Scholarly Concentrations; focus on outcomes in aplastic anemia for patients with PNH clones (now applying for internal medicine residency)

Postdoctoral

2013-2014 Amer Zeidan, MD; currently: Associate Professor; Yale University School of Medicine, New Haven, CT; Project: Edward P Evans MDS Clinical Research Consortium Fellowship for MDS Clinical Research, Multiple manuscripts co-published

2014-2015 Lukasz Gondek, MD, PhD; currently: Assistant Professor, Johns Hopkins University School of Medicine; Project: Edward P Evans MDS Clinical Research Consortium Fellowship for MDS Clinical Research, Multiple manuscripts co-published

2016-2018 Clio Franklin, MBBS; Johns Hopkins University School of Medicine; currently: Post-doctoral student in London; Project: Outcomes in BMT, Manuscript published.

2016-2018 Hany Elmariah, MD, MS- Edward P Evans MDS Clinical Research Consortium Fellowship currently: Assistant Member at Moffitt Cancer Center [8/1/18]; Project: Edward P Evans MDS Clinical Research Consortium Fellowship for MDS Clinical Research

2018-2020 Bryan Hambley, MD- Assistant Professor, University of Cincinnati College of Medicine

2021-2024 Michael Hochman, MD-current Hematology fellow

Advising

2012-2014 Jocelyn Wozney, MD- Fellowship Research; currently: Clinical Associate; Lancaster General Health, Lancaster, PA

2015-present Jonathan Webster, MD- Assistant Professor Research Committee; currently: Assistant Professor of Oncology

2018-present Kristen Schrantz, MD- Fellowship Research Committee; currently: Pediatric Oncology Instructor, Johns Hopkins University School of Medicine

2018-present Alexander Ambinder, MD- Fellowship Research Committee; currently: Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center

2019-present Theodoros Karantanos, MD- Fellowship Research Committee; currently: Medical Oncology Fellow

Educational Program Building None

Educational Demonstration activities Multiple CME endeavors including three Education Program sessions at American Society of Hematology (2015, 2018, 2021)

RESEARCH ACTIVITIES

Research focus

I am an Associate Professor of Oncology in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. My principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure

(aplastic anemia and myelodysplastic syndromes). I have specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, I have taken a rigorous approach to the study of transfusion therapies in these patient populations. I am or have been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). I am one Study Chair for the multi-site phase II BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed severe aplastic anemia. This trial is based on the published data from my investigator-initiated trial on the same topic from my K23 award. Lastly, I am the local PI as well as deputy Co Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, my goal is to improve outcomes for patients with bone marrow failure in a research environment.

Research Program Building / Leadership

11/12- present Role: Site PI. MDS Clinical Trials Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University.

The MDS Clinical Trials Program was borne out of the MDS Clinical Research Consortium grant of which I am the site PI. This is a first of its kind consortium of six member institutions with expertise and collaborations in clinical research for myelodysplastic syndromes. The program connects patients and community providers with advanced cancer from the Hopkins catchment areas to pivotal studies and research initiatives, allowing them access to cutting edge therapies for their MDS. My role also includes supervision and regular performance assessment of our team which includes a Program Data Manager, 1-2 rotating research nurses, and 2 study coordinators. Additionally, there is support for a postdoctoral fellowship appointment for which I am the mentor on MDS related projects.

1/1/17-12/30/17 2017 Junior Co- Chair of MDS Clinical Research Consortium

1/1/18-12/30/18 2018 Senior Co- Chair of MDS Clinical Research Consortium

1/1/14-12/30/19 National MDS Study, Steering committee

1/1/20- present National MDS Study, Deputy Chair

Research Demonstration Activities

- 2005 E2905 Randomized Ph III Trial Comparing Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low or Intermediate-1 Risk MDS and Symptomatic Anemia Phase III. (NCT00843882, Site PI)
- 2005 E1905 A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia. (NCT00313586, Site PI)
- 2007 J07118 A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subject With myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML). (NCT00528983, Site PI)
- 2008 J0882 Phase II trial of High Dose Lenalidomide in Patients with MDS and AML with Trilineage Dysplasia (AML-TLD). (NCT00867308, Site PI)
- 2010 J10117 A Pilot study of Myeloablative Conditioning and Transplantation of HLA-matched, Partially HLA-mismatched, HLA-haploidentical or matched unrelated (MUD) Bone Marrow for Patients with Refractory Severe Aplastic Anemia. (NCT01383434, Site PI)
- 2011 J1118 A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Every Other Week in Myelodysplastic Syndrome Patients with Excell Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine. (NCT01241500, Site PI)
- 2011 S1117 A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Phase II. (NCT01522976, Site PI)
- 2012 S1203 A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). (NCT01802333, Site PI)
- 2013 J13126 Prospective Randomized Clinical Feasibility Study of Red Cell Transfusion Goals in Patients with Acute Leukemias Pilot. (NCT02086773, Study Chair)
- 2013 J13111 Phase II Randomized, Double-Blinded, Placebo-Controlled Study of Pracinostat in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS)

- Intermediate Risk 2 or High-Risk Myelodysplastic Syndrome (MDS). (NCT01873703, Site PI)
- 2013 J13152 A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity Phase I/II. (NCT01776723, Site PI)
- 2013 J1301 An open-label, randomized, Phase 2, parallel, dose-ranging, multicenter, study of sotatercept for the treatment of patients with anemia and low- or intermediate-1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leukemia (CMML) Phase II. (NCT01736683, Site PI)
- 2013 J1323 Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality. (NCT01804101, Site PI)
- 2014 J1424 A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/ Haploidentical Related or Matched Unrelated Bone Marrow for Patients with Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Phase II. (NCT02224872, Study Chair)
- 2014 J14137 A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS) Phase I/II. (NCT02103478, Site PI)
- 2014 J14179 Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m² IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m² SC/IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m² SC/IV daily for 5 days every month) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Dependent versus Best Supportive Care (BSC) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Independent Phase II. (NCT02269280, Site PI)
- 2014 J14141 A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia due to IPSS Lower-risk Myelodysplastic Syndromes. (NCT01804101, Site PI)
- 2015 J15181 A Phase 2, Open-label, Single-arm Rollover Study to Evaluate Long-term Safety in Subjects Who Participated in Other Celgene Sponsored CC-486 (oral azacitidine) Clinical Trials in Solid Tumors and hematological Disorders. [CC-486-GEN-001]. (NCT02494258, Site PI)
- 2015 J15165 Phase II study of shortened-duration immunosuppression following nonmyeloablative peripheral blood stem cell transplant with high-dose posttransplantation cyclophosphamide in malignancies that are challenging to engraft. (NCT02556931, Site PI)
- 2016 NHLBI-MDS: The National Myelodysplastic Syndromes (MDS) Natural History Study. (NCT02775383, Site PI)
- 2016 J1688 A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia Phase II. (NCT02833805, Site PI)
- 2016 J1661 A Phase 3, Double-Blind, Randomized study to compare the efficacy and safety of luspatercept (ACE-536) versus placebo for the treatment of anemia due to IPSS-R Very low, Low or Intermediate risk myelodysplastic syndromes in subjects with ring sideroblasts who require red blood cell transfusions The "MEDALIST" Trial Phase III. (NCT02631070, Site PI)
- 2016 J1664 Principal Investigator Dezern, Amy A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine versus Single-Agent Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia (Pevonedistat-2001) Phase II. (NCT02610777, Site PI)
- 2017 J1793 A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination with Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms. (NCT03072043, site PI)
- 2017 J1782 A Phase II Study of Tipifarnib in Subjects with Chronic Myelomonocytic Leukemia [KO-TIP-004]. (NCT02807272, Site PI)
- 2017 J17103 CD8 depleted, non-engrafting, HLA mismatched unrelated donor lymphocyte infusion in patients with MDS and secondary AML. (NCT04620681, Site PI)
- 2017 J1725 Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (CHAMP) Phase II. (NCT02918292(pending), Study Chair)
- 2018 J1832 A Phase 2, Open-label, Single-arm Rollover Study to Evaluate Long-term Safety in a single Subject Who Participated in a Celgene sponsored clinical trial entitled, "An open-label, randomized, Phase 2,

parallel, dose-ranging, multicenter, study of sotatercept for the treatment of patients with anemia and low- or intermediate-1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leukemia (CMML).”(NCT01736683, Site PI)

- 2018 J18170 TPI-ALV-102: A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients with Myelodysplastic Syndromes (MDS). (NCT03593915, Site PI)
- 2018 J1873 Targeted therapy with the mutant IDH2-inhibitor enasidenib (AG221) for high-risk IDH2-mutant myelodysplastic syndrome. (NCT03383575, Site PI)
- 2018 J18113 A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)[ASTX727-02]. (NCT03306264, Site PI)
- 2019 J19112 Phase II trial of APR-246 in combination with azacitidine as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplant [A19-11172]. (NCT03931291, Site PI)
- 2019 J1919 A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome. (NCT03787498, Site PI)
- 2019 J1984 A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes [study number A18-15331]. (NCT03745716, Site PI)
- 2019 An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 [ASTX727-06]. (NCT04093570, Site PI)
- 2020 J2004 MCC19727: A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion. (NCT03722407, Site PI)
- 2020 NCTNMDS NHLBI-MDS: The National Myelodysplastic Syndromes (MDS) Natural History Study. (NCT02775383, Site PI, Steering committee, 2020 Deputy Chair)

Inventions, Patents, Copyrights None
Technology Transfer None
System Innovation and Quality Improvement Activities None

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

- 2009-present Osler Medical Residency Intern Selection Committee
- 2010 Search Committee for the Director for the Osler Medical Residency Training Program
- 2011-present Medical Oncology/Hematology Fellowship Selection Committee
- 2013 Co-Chair, Junior Faculty Retreat for Sidney Kimmel Comprehensive Cancer Center
- 2013-present Transfusion Practices Committee
- 2014-present SKCCC Patient/Caregiver Advisory Council
- 2014-2016 Junior Faculty Resource Advisory Council for Office of Faculty Development (Oncology representative)
- 2014-2015 Outpatient Department Provider Council
- 2014-present Faculty Compensation Committee- Oncology
- 2018-2021 Faculty Senate
- 2018-present SKCCC Women’s initiative
- 2018-2019 Hemostasis Trial Outcomes Working Group Member, NHLBI State of the Science, Bethesda, MD
- 2019-2021 SKCCC Educational committee, Grand Rounds Co-Director

Editorial Activities

- 2019-2022 Contributing Editor, *The Hematologist*, American Society of Hematology

Editorial Board Activities

- 2021-present VJHemOnc, Board Member
- 2021 Frontiers in Oncology Guest Editor

Journal Review Activities

2012-present PLOS One, Ad Hoc Reviewer
 2012-present Pharmacology, Ad Hoc Reviewer
 2012-present Pediatric Blood and Cancer, Ad Hoc Reviewer
 2012-present Journal of Leukemia, Ad Hoc Reviewer
 2012-present Journal of Hematopathology, Ad Hoc Reviewer
 2013-present British Journal of Hematology, Ad Hoc Reviewer
 2014-present Annals of Medicine, Ad Hoc Reviewer
 2014-present Thrombosis and Haemostasis, Ad Hoc Reviewer
 2014-present Biology of Blood and Marrow Transplantation, Ad Hoc Reviewer
 2015-present Bone Marrow Transplantation, Ad Hoc Reviewer
 2015-present Leukemia, Ad Hoc Reviewer
 2015-present European Journal of Haematology, Ad Hoc Reviewer
 2015-present Transfusion, Ad Hoc Reviewer
 2015-present Blood, Ad Hoc Reviewer
 2015-present Haematologica, Ad Hoc Reviewer
 2015-present Blood Reviews, Ad Hoc Reviewer
 2016-present Journal of Clinical Oncology, Ad Hoc Reviewer
 2017-present Annals of Internal Medicine, Ad Hoc Reviewer
 2017-present JAMA Oncology, Ad Hoc Reviewer
 2018-present Transplant International, Ad Hoc Reviewer
 2018-present Cancer, Ad Hoc Reviewer
 2019-present Clinical Cancer Research, Ad Hoc Reviewer
 2019-present Therapeutic Advances in Hematology, Ad Hoc Reviewer
 2019-present The Oncologist, Ad Hoc Reviewer
 2019-present British Journal of Hematology, Ad Hoc Reviewer
 2019-present New England Journal of Medicine, Ad Hoc Reviewer

Advisory Committees, Review Groups/Study Sections

2013-present Medical Advisory Board, AA-MDS International Foundation
 2013-present National Comprehensive Cancer Network MDS Guidelines committee
 2014-present AAMDS Grant Review
 2014-present ASH Clinical Research Training Institute Grant Review
 2014-2015 Peer Reviewer Department of Defense: Bone Marrow Failure Research Program
 2015-present AAMDSIF Patient Education Council
 2016 Peer Reviewer NIH Clinical Oncology R01 Study Section
 2016- 2022 Scientific Advisory Board for MDS Research Fund of Dresner Foundation
 2018-present Scientific Advisory Board of the Fanconi Anemia Research Fund (FARF)
 2017-present Abstract Reviewer, ASH Annual Meeting
 2018 Abstract Reviewer for ASBMT & CIBMTR
 2019 ASH Women in Hematology Working Group
 2020 Education Program Committee, American Society of Hematology
 2020-2021 Peer Reviewer Department of Defense: Bone Marrow Failure Research Program
 2021 Abstract Reviewer for EBMT Meeting, 2022- Prague
 2021 ASH Honoric Award Study Section
 2021 ASH Education Committee
 2021 ASH Communications Committee
 2021-2022 Expert panel member American Society for Transplantation and Cellular Therapy Practice Guidelines Committee for transplant in MDS

Professional Societies

2008-present Member, American Society of Hematology
 2008-present Member, American Society of Clinical Oncology
 2009-present Member, American Board of Internal Medicine
 2017-present Member, American Society for Transplantation and Cellular Therapy (formally ASBMT)

Conference Organizer

2022 Chair, Highlights of ASH North America. Washington, DC

2022 Chair, Highlights of ASH North America. Dallas, TX
 2022 AAMDS IF International Meeting Program Committee Chair
 2023 Chair, American Society of Hematology National Meeting Malignant Hematology, Education Chair

Session Chair

2020 Non-Malignant Disorders Committee. BMT CTN 2021 State of the Science Symposium
 2020 Bone marrow failure Abstract Review Coordinator, ASH 2020 Annual Meeting
 2021 Non-Malignant Education Program Advisory Panel, ASH 2021 Annual Meeting

Consultantships

2014-2016 H3 Biosciences
 2015-present Celgene → Bristol Meyers Squibb (2020)
 2016 Accorda/ Biotie
 2016-2017 Boehringer-Ingelheim
 2018-2019 Acceleron
 2018 Syros
 2018-present MEI Pharma, INC
 2019 Abbvie
 2020 Novartis
 2020 Geron, Chair of IDMC for IMerge trial
 2022 Severe Aplastic Anemia Delphi panel- selected as clinical expert
 2022 Health and Human Services Vaccine consultant for hematologic disorders potentially caused by immunizations

RECOGNITION

Awards and Honors

1998 Phi Beta Kappa Honor Society
 2000 Commencement Speaker College of Natural Sciences at the University of Texas at Austin
 2000 Most Outstanding Student Award at the University of Texas at Austin
 2005 Sol Goldman Award for Excellence in Geriatrics School of Medicine, Johns Hopkins University, School of Medicine
 2008 Daniel Baker Jr. Memorial Award for outstanding, attentive, and devoted patient care
 2009 American Society of Hematology Travel Award
 2010 Alpha Omega Alpha
 2010 American Society of Hematology Clinical Research Training Institute
 2013 Director's Teaching Award, Oncology, The Sidney Kimmel Comprehensive Cancer Center
 2014 Emerging Women's Leadership Program, The Johns Hopkins University School of Medicine
 2018 2018 NCI Cancer Clinical Investigator Team Leadership Award
 2020 Deputy Chair, The National MDS Study
 2020 Director's Teaching Award, Oncology, The Sidney Kimmel Comprehensive Cancer Center
 2021 Office of Women in Science and Medicine (OWISM) 2021 Leadership Program
 2021 Miller Coulson Academy of Clinical Excellence Class of 2021

Invited Talks and Panels *CME accredited

JHMI/Regional

5/10 *Osler's Greatest Hits, 55th Annual Philip A Tumulty Topics in Clinical Medicine, Johns Hopkins Medical Institutions, Baltimore, MD
 2009-2010 Image of Osler, Johns Hopkins Hospital Medical Grand Rounds Johns Hopkins, Monthly
 5/11 Bone Marrow Transplant for Refractory Severe Aplastic Anemia American Society of Hematology, Washington DC American Society of Hematology Clinical Research Training Institute
 5/12 *Bone Marrow Failure Hematology Grand Rounds, Johns Hopkins Medical Institutions, Baltimore
 4/13 *Bone Marrow Failure Johns Hopkins Hematologic Malignancies Symposium, Johns Hopkins Medical Institutions, Baltimore, MD
 9/13 Aplastic Anemia Therapeutics and Future Directions Boston, MA Aplastic Anemia and MDS International Foundation
 3/14 *Haploidentical Bone Marrow Transplants for Bone Marrow Failure Bethesda, MD Aplastic Anemia and MDS International Foundation

- 5/14 *Approach to Pancytopenia in Adults: It's Not All MDS; 59th Annual Philip A Tumulty Topics in Clinical Medicine Baltimore, MD Johns Hopkins Medical Institutions
- 1/15 *ASH Highlights: MDS; Saint Agnes Hospital, Baltimore, MD
- 1/15 *Pancytopenia; Medstar Harbor Hospital Grand Rounds, Baltimore, MD
- 3/15 PNH: Current Thinking on the Disease, Diagnosis, and Treatment; Aplastic Anemia and MDS International Foundation; Baltimore, MD
- 3/15 *Bone Marrow Failure Hematology Grand Rounds, Johns Hopkins Medical Institutions
- 4/15 *Bone Marrow Failure; Medicine Grand Rounds, Johns Hopkins Medical Institutions- Bayview; Baltimore, MD
- 4/15 Myelodysplastic Syndrome, MDS Overview, Patient Forum; 2015 MDS International Symposium; Washington, DC
- 11/15 National MDS Study, ECOG-ACRIN Cancer Research Group Meeting, Orlando, FL
- 8/16 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes 2016 Alexandria, VA
- 4/17 *Aplastic Anemia; Immunology Grand Rounds, Johns Hopkins Medical Institutions
- 8/17 *US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes 2016 Philadelphia, PA
- 2/18 *George Washington University: Hematology Update 2018: Myelodysplasia, Washington DC
- 1/19 *Treatments Targeting MDS Genetics: A Fool's Errand?; Hematology Grand Rounds, Johns Hopkins Medical Institutions
- 2/20 Mount Sinai Hematology/Oncology Grand Rounds. NY
- 3/20 Howard University Grand Rounds. Washington, DC
- 8/20 *Hematology and Medical Oncology Best Practices Course. Pentagon City, Washington DC.
- 5/21 MDS/CMML Grand Rounds, virtual speaker.
- 6/21 *Treatments for patients with MDS: are we making progress? Hematology/Oncology Grand Rounds. Sibley Hospital, DC.
- 1/22 Speaker: 2022 Highlights of ASH in North America, Washington, DC.
- 1/22 Speaker: Medicine Grand Rounds, Johns Hopkins Medical Institutions-Bayview; Baltimore, MD.

National

- 2/12 *Approach to Diagnostics and Therapeutics in Bone Marrow Failure Syndromes, Leukemia Grand Rounds, Massachusetts General Hospital. Boston, MA
- 12/14 Diagnostics and Therapeutics in Aplastic Anemia; American Society of Hematology Clinical Research Training Institute, San Francisco, CA
- 2/15 *Myelodysplastic Syndromes Updates, ASH Highlights, University of Nebraska Medical Center, Omaha
- 4/15 *Management of lower-risk MDS without del5q and refractory to ESAs; Great Debates and Updates in Hematologic Malignancies Symposium, New York
- 9/15 Aplastic Anemia: Current Thinking on the Disease, Diagnosis, and Non- Transplant Treatment, AAMDS Symposium, Boston, MA
- 9/15 Transfusion Triggers in AML, Society for the Advancement of Blood Management Annual Meeting, Orlando, FL
- 10/15 *Aplastic Anemia and MDS, Allegheny Health Network Hospital, Pittsburgh, PA
- 12/15 *Myelodysplastic Syndromes- Evolving Diagnosis and Therapy; American Society of Hematology 2015 Annual Meeting, Orlando, FL
- 7/16 *Bone Marrow Failure, Grand Rounds, University of Denver, Anschutz Medical Center, Denver CO
- 8/16 *An approach to diagnosis and staging of MDS: From morphology to genetics, US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Alexandria, VA
- 10/16 National MDS Study, Edward P. Evans Foundation: MDS Research Summit 2016, Nashville, TN
- 1/17 *Myelodysplastic Syndromes, 2016 Highlights of ASH in North America, Atlanta, GA
- 1/17 *Myelodysplastic Syndromes, 2016 Highlights of ASH in North America: Myelodysplastic Syndromes, Dallas, TX
- 1/17 *Myelodysplastic Syndromes, 2016 Highlights of ASH in North America: Myelodysplastic Syndromes, New York, NY
- 3/17 Bone Marrow Failure: PNH, National Organization for Rare Disorders, National Meetings, Baltimore
- 8/17 *New opportunities in experimental therapeutics in MDS US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Philadelphia, PA
- 9/17 *How I treat MDS refractory to hypomethylating agents, 2017 ASH Meeting on Hematologic Malignancies, Chicago, IL

10/17 *The Many Faces of MDS, Bone Marrow Failure and Myeloid Neoplastic Disease Symposium, Vanderbilt University, Nashville, TN

12/17 Diagnosis, Classification, and Clinical Care of MDS; American Society of Hematology Friday Satellite Symposium 2017; Atlanta, GA

2/18 Role of Registries in MDS; MDS/MPN International Working Group, Charlotte, NC

2/18 Myelodysplasia: Novel therapies; George Washington Hematology Update 2018, Fairfax, VA

4/18 *Novel Therapies and Combinations for MDS; Great Debates and Updates in Hematologic Malignancies Symposium, New York

4/18 *How to Approach Intermediate Risk MDS; Great Debates and Updates in Hematologic Malignancies Symposium, New York

12/18 *Molecular Maelstrom of Myelodysplastic Syndromes; American Society of Hematology 2018 Annual Meeting, San Diego, CA

1/19 Keynote address for SUNY Upstate Medical University Biannual BMT Symposium; A Path to Cure: The Hopkins Haplo BMT Experience for Aplastic Anemia, Syracuse, NY

6/19 Approaching Clonal Hematopoiesis: Can you be too precise? ASCO Annual Meeting 2019, Chicago, IL

9/19 *How I Treat Patients with High Grade Myelodysplastic Syndrome. 2019 ASH Meeting on Hematologic Malignancies, Chicago, IL

9/19 Multidisciplinary Approach to Testing and Diagnosis, Evaluation of Risk and Personalized Treatment Selection. 2019 GASCO Annual Meeting & ASCO Direct Highlights, Alpharetta, GA

1/20 Acquired Bone Marrow Failure Syndromes. 2020 Highlights of ASH, Dallas, TX

3/20 COVID-19 Update: Bone Marrow Failure and Infectious Disease. AAMDSIF Spring Virtual Meeting

5/20 What an Oncologist Would Like an Intensivist to Know, American Thoracic Society Virtual Meeting

6/20 Improving Patient Outcomes in MDS Through Better Diagnosis, Risk Stratification, and New Treatment Options, Medical Crossfire® Virtual Filming

7/20 Conventional and Haplo-BMT for SAA. AAMDSIF Scientific Symposium Virtual Meeting

8/20 Current and Emerging Strategies in Low-Risk Settings. SOHO 2020 Virtual Symposium.

12/20 “Myelodysplastic Syndromes—Clinical Studies: Personalized Clinical-Decision Tools and treatment of lower risk MDS” Oral Presentation, 2020 ASH Annual Virtual Meeting (Friday Satellite Symposium)

1/21 “Updates from ASH 2020: Promising Treatment Advances for MDS and AML.” MDS Foundation – 2021 Webinar

1/21 Physician Expert discussion: TP53 as a therapeutic target. Healthcare Insights virtual talk.

2/21 SAB Presenter/Advisory Board Member: 2021 FARE Annual Leadership virtual meeting

2/21 “CCO Independent Conference Highlights of the 2020 Virtual ASH Annual Meeting.”. Clinical Care Options, virtual speaker

2/21 Featured speaker on Myelodysplasia: 8th Annual Virtual Hematology review.

3/21 Committee Chair-Non-Malignant Disorders. BMT CTN 2021 State of the Science Virtual Symposium (SOSS)

3/21 “Haploidentical HSCT and idiopathic aplastic anaemia” invited speaker. EBMT virtual meeting

4/21 HSCTCT, Oncology Grand Rounds, Virtual

5/21 Speaker on haplo AA debate: ISCT virtual meeting, New Orleans

6/21 Speaker: Current Standard of Care and Clinical Updates, ASCO Satellite Symposium.

7/21 Speaker: Great Debates & Updates in Hematologic Malignancies

8/21 Speaker: Ground Rounds, Medical University of South Carolina, virtual.

10/21 Speaker: Medicine Ground Rounds, Memorial Sloan Kettering Cancer Center, virtual.

12/21 Program Chair and Speaker: “MDS: Beyond a One-Size-Fits-All Approach”. 2021 ASH Annual Meeting, Atlanta, GA

1/22 Chair and Speaker: 2022 Highlights of ASH in North America, Dallas TX.

2/22 “Choosing donors in older patients: spoiled for choice?” invited speaker. 2022 Transplantation and Cellular Therapy Meeting of ASTCT and CIBMTR; Salt Lake City, UT.

2/22 Expert Forum on AML and Myelofibrosis; Amelia Island, FL.

4/22 “MDS Diagnosis and Risk Stratification: the most crucial step” invited speaker. 2022 MPN-MD US Focus Live Meeting. San Diego, CA.

4/22 Invited Speaker: Cancer Center Seminar Series, University of Minnesota, Minneapolis, MN.

4/22 “Drug Development in Myelodysplastic Syndrome” invite speaker. FDA Mini Symposium, US virtual talk

4/22 MPN-MDS Live US Focus Meeting 2022 - San Diego, CA

5/22 “High-Risk MDS Meeting Series: Faculty presenter and Webinar invitation, virtual

- 5/22 Hybrid Community Oncology Forums: The Evolving Treatment Landscape for Higher-Risk Myelodysplastic Syndrome
- 5/22 Expert Faculty MDS Q&A

International

- 10/15 *Diagnosis and Clinical Management of MDS, IV Ibero-American Symposium on Myelodysplastic Syndrome, Puerto Vallarta, Mexico
- 4/17 *Myelodysplastic Syndromes, 2016 Highlights of ASH in Latin America, Montevideo, Uruguay
- 10/18 *Beyond hypomethylating therapies in MDS, VI Simposio Latinoamericano de SMD y I Simposio Latinoamericano de Fallos Medulares, Cancun, Mexico
- 11/20 “What Do All These Mutations Mean?” AMP 2020 Annual Virtual Meeting & Expo
- 3/21 “Haploidentical HSCT and idiopathic aplastic anaemia” invited speaker. EBMT virtual meeting
- 4/21 “MDS diagnosis and risk stratification”. MPN-MDS-AML US Focus Virtual Meeting
- 4/21 “Haplo HSCT”-Faculty Member and Speaker, Live Q & A: EHA-SWG Scientific Virtual Meeting on Acquired Aplastic Anemia.
- 9/21 “Lower Risk MDS” - Insights in Hematology Meeting, Cluj Napoca, Romania, virtual talk.
- 9/21 “Managing MDS” Invited Speaker, The 16th International Congress on Myelodysplastic Syndromes, Toronto, Canada virtual meeting.
- 10/21 “Haploidentical cell transplantation for severe acquired aplastic anemia: The USA Experience” invited speaker. Bone Marrow Failure Session Program of XXV SBTMO Congress, Brazil Virtual Meeting.
- 10/21 “Novel Treatments for Aplastic Anemia” invited speaker. 2021 “ASH Day at AMEH” Mexico, virtual meeting.
- 10/21 “Aplastic Anemia: Path to Cure” -Invited Speaker. 2021 Leukemia Academic Rounds, Princess Margaret Cancer Centre, Toronto, Canada virtual.
- 11/21 “Haploidentical cell transplantation for severe acquired aplastic anemia: The USA Experience” invited speaker. What’s new in 2021 in TCSH?”, Cluj Napoca, Romania, virtual talk.
- 5/22 “Hematopoietic stem cell transplant in severe aplastic anemia" invited speaker. Mexico, virtual talk